Genetics company 23andMe is expected to be purchased by Regeneron Pharmaceuticals, according to announcements shared by both ...

This was the stock's second consecutive day of losses.

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.65% to $604.62 Wednesday, on what proved to be an all-around dismal ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March following a series of setbacks.

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron Pharmaceuticals has bought the genetic testing company 23andMe, a company once valued at $6bn, for $256m through a ...

A 2023 data breach hurt demand for 23andMe's core services Transaction is expected to complete in the third quarter May 19 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on ...

Genetic testing company 23andMe filed for bankruptcy in March. Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based ...